Form 4: Xilio Therapeutics Executive Granted Stock Options

Kevin M. Brennan, SVP of Finance and Accounting at Xilio Therapeutics, was granted stock options for 20,000 shares on May 1, 2024.

Summary

• Kevin M. Brennan, SVP of Finance and Accounting at Xilio Therapeutics, Inc., filed a Form 4 on May 3, 2024.
• The filing reports a transaction that occurred on May 1, 2024, where Brennan was granted stock options to purchase 20,000 shares of Xilio Therapeutics common stock at an exercise price of $1.08 per share.
• The options vest monthly from June 1, 2024, until May 1, 2028, with the options expiring on April 30, 2034.
• Following the transaction, Brennan directly owns derivative securities for 20,000 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and suggests confidence in the executive's ability to contribute to the company's success.

Positives

• The granting of stock options to a key executive can be seen as a positive sign, aligning their interests with the company's long-term success.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to incentivize performance and retain key personnel. This grant aligns with standard practices in the sector.

Comparison to Industry Standards

• Stock option grants are a typical component of compensation packages for executives in biotech companies like Xilio Therapeutics.
• Comparable companies such as Arcus Biosciences or Gritstone Bio also utilize stock options to incentivize their leadership teams.
• The vesting schedule and exercise price appear to be within the typical range for similar grants in the industry.

Stakeholder Impact

• Shareholders may view this as a positive sign, aligning executive interests with company performance.
• Employees may see this as a sign of stability and commitment to leadership.

Key Dates